Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational Clinical Trial to Evaluate PLX cells for the Treatment of Patients Suffering from Complications Associated with COVID-19

Next Previous
Trial Profile

A Multinational Clinical Trial to Evaluate PLX cells for the Treatment of Patients Suffering from Complications Associated with COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
  • 05 May 2020 According to an Pluristem Therapeutics media release, the company announced that it has entered into definitive agreements with two institutional investors in connection with a registered direct offering. The company intends to use the net proceeds from the offering for working capital, including funding towards its Phase II study of PLX cell therapy in the treatment of complications arising from COVID-19 and other clinical trial activities.
  • 24 Apr 2020 According to a Pluristem Therapeutics media release, as the company moves forward into this multinational clinical trial for PLX cells to treat patients suffering from complications associated with COVID-19, it expects the EIB financing (Euro 50 million non-dilutive financing) will accelerate the path to approval and to making a potentially effective COVID-19 treatment available worldwide.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top